Literature DB >> 32540982

From Etest to Vitek 2: Impact of Enterococcal Linezolid Susceptibility Testing Methodology on Time to Active Therapy.

Cynthia T Nguyen1, Cindy Bethel2, Natasha N Pettit3, Angella Charnot-Katsikas2.   

Abstract

Different linezolid antimicrobial susceptibility testing (AST) methodologies yield various results. In 2018, we transitioned our linezolid AST methodology from the Etest to Vitek 2. We sought to evaluate the impact of this change on antibiotic use among 181 inpatients with vancomycin-resistant enterococcal (VRE) infections. The transition from Etest to Vitek 2 resulted in an increase in linezolid susceptibility (38% versus 96%; P < 0.001) and a reduction in time to active antibiotic therapy (3 versus 2.6 days; P = 0.007).
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  linezolid; microbial sensitivity tests; vancomycin-resistant enterococci

Mesh：

Substances：

Year:  2020        PMID： 32540982      PMCID： PMC7449175          DOI： 10.1128/AAC.00302-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

2.  Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid.

Authors:  Stefan Riedel; Kar Mun Neoh; Stephen W Eisinger; Lisa M Dam; Tsigereda Tekle; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2014-04-09       Impact factor: 5.948

Review 3.  Vancomycin-resistant enterococcal bacteremia pharmacotherapy.

Authors:  Ruchi Patel; Jason C Gallagher
Journal:  Ann Pharmacother       Date:  2014-10-28       Impact factor: 3.154

4.  Investigation of Linezolid Resistance in Staphylococci and Enterococci.

Authors:  Christopher D Doern; Jason Y Park; Michael Gallegos; Debbie Alspaugh; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2016-03-02       Impact factor: 5.948

5.  Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections.

Authors:  Evan J Zasowski; Kimberly C Claeys; Abdalhamid M Lagnf; Susan L Davis; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2016-03-03       Impact factor: 9.079

Review 6.  Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.

Authors:  Eleni P Balli; Chris A Venetis; Spiros Miyakis
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 7.  Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.

Authors:  Yu-Chung Chuang; Jann-Tay Wang; Hsin-Yi Lin; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090
  7 in total
  1 in total

Review 1.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.